Neuromyelitis optica spectrum disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:15:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neuromyelitis optica spectrum disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Satralizumab for Children with Neuromyelitis Optica Spectrum Disorder (NMOSD) https://clinicaltrials.eu/trial/study-of-satralizumab-for-children-with-neuromyelitis-optica-spectrum-disorder-nmosd/ Wed, 29 Apr 2026 15:01:50 +0000 https://clinicaltrials.eu/trial/study-of-satralizumab-for-children-with-neuromyelitis-optica-spectrum-disorder-nmosd/ This clinical trial is focused on studying a condition called Neuromyelitis Optica Spectrum Disorder (NMOSD), which is a rare disease that affects the nerves in the eyes and spinal cord. The study is specifically looking at children who have a positive test for a specific antibody called Aquaporin-4 (AQP4). The treatment being tested in this study is a medication called Satralizumab, which is given as a solution for injection under the skin. Satralizumab is a type of protein that works by blocking a receptor involved in inflammation, and it is also known by its code name RO 533-3787.

The purpose of this study is to understand how Satralizumab behaves in the body, its safety, and how well it works in children with NMOSD. The study will observe how the medication is absorbed and processed in the body over a period of 24 weeks. Participants will receive regular injections of Satralizumab and will be monitored for any changes in their condition, including the frequency of relapses, which are episodes when symptoms get worse. The study will also look at changes in disability levels, vision, pain, and overall quality of life.

Throughout the study, participants will have regular check-ups to monitor their health, including tests to measure their vision, pain levels, and general well-being. The study will also track any side effects or adverse reactions to the medication. The goal is to gather information that could help improve treatment options for children with NMOSD in the future.

]]> Study on Imlifidase for Treating Acute Inflammation in Patients with Neuromyelitis Optica Spectrum Disorder https://clinicaltrials.eu/trial/study-on-imlifidase-for-treating-acute-inflammation-in-patients-with-neuromyelitis-optica-spectrum-disorder/ Wed, 29 Apr 2026 14:59:43 +0000 https://clinicaltrials.eu/trial/study-on-imlifidase-for-treating-acute-inflammation-in-patients-with-neuromyelitis-optica-spectrum-disorder/ This clinical trial is focused on studying a condition known as Neuromyelitis Optica Spectrum Disorder (NMOSD), which is sometimes referred to as Devic disease. This is a rare autoimmune disease that primarily affects the optic nerves and spinal cord, leading to symptoms such as vision loss and muscle weakness. The trial will investigate the effects of a treatment called Imlifidase, which is administered as a solution through an intravenous infusion. Imlifidase is designed to target and reduce specific antibodies in the blood that are believed to contribute to the inflammation seen in NMOSD.

The purpose of the study is to evaluate how effective Imlifidase is in reducing these harmful antibodies in patients experiencing severe symptoms of NMOSD, such as optic neuritis (inflammation of the optic nerve) and myelitis (inflammation of the spinal cord). Participants in the study will receive the treatment and will be monitored to see if the levels of these antibodies decrease within six hours after receiving Imlifidase. Some participants may receive a placebo instead of the actual treatment to help compare the effects.

Throughout the study, participants will be closely observed to assess the impact of the treatment on their condition. The trial aims to provide valuable insights into whether Imlifidase can effectively manage acute inflammation in NMOSD, potentially offering a new therapeutic option for those affected by this challenging disease.

]]> Study on the Effectiveness and Safety of Ravulizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD) https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ravulizumab-for-children-and-adolescents-with-neuromyelitis-optica-spectrum-disorder-nmosd/ Wed, 29 Apr 2026 14:30:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ravulizumab-for-children-and-adolescents-with-neuromyelitis-optica-spectrum-disorder-nmosd/ This clinical trial is focused on studying a condition called Neuromyelitis Optica Spectrum Disorder (NMOSD), which affects the nervous system, particularly the eyes and spinal cord. The study is testing a treatment called Ravulizumab, also known by its code name ALXN1210. Ravulizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein. The purpose of the study is to evaluate how effective and safe Ravulizumab is for children and adolescents who have NMOSD.

Participants in the study will receive Ravulizumab and will be monitored over a period of time to see how the treatment affects their condition. The study will look at various aspects, such as the frequency of relapses, which are episodes when symptoms worsen, and changes in physical abilities and vision. The study will also assess the overall health and quality of life of the participants. Safety is a key focus, and any side effects or changes in health will be closely observed.

This study is designed to provide important information about the use of Ravulizumab in young patients with NMOSD, aiming to improve understanding of how this treatment can help manage the disease. Participants will be part of a group that receives the treatment, and their progress will be compared to historical data from similar patients who have not received Ravulizumab. The study is expected to continue until 2028, allowing researchers to gather comprehensive data on the treatment’s long-term effects.

]]> Study of Inebilizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder https://clinicaltrials.eu/trial/study-of-inebilizumab-for-children-and-adolescents-with-neuromyelitis-optica-spectrum-disorder/ Wed, 29 Apr 2026 14:29:25 +0000 https://clinicaltrials.eu/trial/study-of-inebilizumab-for-children-and-adolescents-with-neuromyelitis-optica-spectrum-disorder/ This clinical trial is focused on studying a condition known as Neuromyelitis Optica Spectrum Disorder (NMOSD), which is also referred to as Devic’s syndrome. NMOSD is a rare disease that affects the central nervous system, particularly the optic nerves and spinal cord, leading to symptoms such as vision loss and muscle weakness. The study involves a treatment using a medication called Inebilizumab, which is a type of drug known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific cells in the body, and in this case, Inebilizumab is being tested for its effects on NMOSD in children and adolescents.

The purpose of this study is to understand how Inebilizumab behaves in the body, its effects on the disease, and its safety for young patients with NMOSD. Participants in the study will receive Inebilizumab through a direct injection into a vein. The study will monitor how the drug is processed by the body, its impact on the disease, and any side effects that may occur. This will help researchers determine the best way to use Inebilizumab for treating NMOSD in younger patients.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. These check-ups will include measuring the levels of certain cells in the blood and evaluating any changes in symptoms or overall health. The study aims to provide valuable information that could lead to better treatment options for children and adolescents living with NMOSD.

]]>